Article in Cancer discovery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
14 authors.
Mei Luo *Brown Center for Immunotherapy, School of Medicine, Indiana University, Indianapolis, Indiana.ORCID 0000-0002-0183-2373
Jingwen Yang *Brown Center for Immunotherapy, School of Medicine, Indiana University, Indianapolis, Indiana.ORCID 0009-0001-9296-571X
Alejandro A SchäfferCancer Data Science Laboratory, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, Maryland.ORCID 0000-0002-2147-8033
Chengxuan ChenBrown Center for Immunotherapy, School of Medicine, Indiana University, Indianapolis, Indiana.ORCID 0000-0002-9650-1437
Yuan LiuBrown Center for Immunotherapy, School of Medicine, Indiana University, Indianapolis, Indiana.ORCID 0000-0003-2030-1153
Yamei ChenBrown Center for Immunotherapy, School of Medicine, Indiana University, Indianapolis, Indiana.ORCID 0000-0002-9072-5157
Chunru LinDepartment of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-6473-8229
Lixia DiaoDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-6995-4492
Yong ZangDepartment of Biostatistics and Health Data Science, School of Medicine, Indiana University, Indianapolis, Indiana.ORCID 0000-0003-0572-4756
Yanyan LouDivision of Hematology and Oncology, Mayo Clinic, Jacksonville, Florida.ORCID 0000-0001-6207-9461
Huda SalmanBrown Center for Immunotherapy, School of Medicine, Indiana University, Indianapolis, Indiana.ORCID 0000-0001-5305-3198
Gordon B MillsKnight Cancer Institute, Oregon Health and Science University, Portland, Oregon.ORCID 0000-0002-0144-9614
Eytan RuppinCancer Data Science Laboratory, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, Maryland.ORCID 0000-0002-7862-3940
Leng HanBrown Center for Immunotherapy, School of Medicine, Indiana University, Indianapolis, Indiana.ORCID 0000-0002-7380-2640
Funding
Tumor Microenvironment and Metastasis ProgramP30CA082709 · NCI · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI David W Clapp · 1999 to 2026
$59.3M
Long Noncoding RNA Advocates Immune Resistant MicroenvironmentR01CA231011 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LIN, CHUNRU · 2019 to 2023
$2.9M
Targeting Small Nucleolar RNA Augments Immunotherapeutic EfficacyR01CA255080 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Chunru Lin · 2022 to 2026
$2.3M
Systematic Characterization of Small Nucleolar RNAs in CancerR01CA262623 · NCI · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI HAN, LENG · 2021 to 2025
$2.0M
MolQTL: A comprehensive resource for molecular quantitative trait loci inhuman cancer.R01HG011633 · NHGRI · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI HAN, LENG · 2021 to 2025
$1.9M
Use Bayesian methods to facilitate the data integration for complex clinical trialsR01GM150808 · NIGMS · INDIANA UNIVERSITY INDIANAPOLIS · PI Yong Zang · 2023 to 2026
$1.3M
Curve-free phase I/II clinical trial designs for molecularly targeted agents and immunotherapyR21CA264257 · NCI · INDIANA UNIVERSITY INDIANAPOLIS · PI ZANG, YONG · 2021 to 2022
$277k
Health and Environmental Sciences Institute (HESI) 61561National Institutes of Health (NIH) R01CA231011National Institutes of Health (NIH) R01HG011633NCI NIH HHS P30 CA082709NCI NIH HHS R01 CA231011NCI NIH HHS R01 CA255080NCI NIH HHS R01 CA262623NCI NIH HHS R21 CA264257NHGRI NIH HHS R01 HG011633NIGMS NIH HHS R01 GM150808Ralph W. and Grace M. Showalter Research Trust Fund (Showalter Foundation)
6 · The paper itself
Abstract
significanceOur study charts a global landscape of ancestry-associated differences in therapeutic efficacy, highlighting the importance of considering ancestry in anticancer therapies.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Ancestral Differences in Anticancer Treatment Efficacy and Their Underlying Genomic and Molecular Alterations. · full record | OpenQuestion